Peripheral blood-derived hematopoietic stem cells for treatment of multiple sclerosis
The aim of this study is to elucidate the mechanisms of action of autologous peripheral blood-derived hematopoietic stem cell (PB-HSCs) transplantion and immunoablation by high-dose cyclophosphamide in treating multiple sclerosis (MS) patients.
Read More
No additional information regarding the therapeutic cells was provided by the sponsor.
Read More
Product Information for
Peripheral blood-derived hematopoietic stem cells for treatment of multiple sclerosis